
  
    
      
        Background_NNP
        The_DT lower_JJR urinary_JJ tract_NN serves_VBZ to_TO store_VB and_CC periodically_RB
        eliminate_VB urine_NN ._. The_DT activity_NN of_IN the_DT urinary_JJ bladder_NN and_CC
        the_DT external_JJ urethral_NN sphincter_NN must_MD be_VB properly_RB
        coordinated_VBN in_IN order_NN for_IN continence_NN to_TO be_VB maintained_VBN and_CC
        timely_JJ micturition_NN to_TO occur_VB ._. Effective_NNP micturition_NN requires_VBZ
        the_DT coordination_NN of_IN central_JJ and_CC peripheral_JJ nervous_JJ system_NN
        structures_NNS that_WDT activate_VBP sympathetic_JJ ,_, parasympathetic_JJ and_CC
        somatic_JJ motor_NN pathways_NNS innervating_VBG the_DT bladder_NN and_CC the_DT
        urethra_NN (_( for_IN a_DT recent_JJ review_NN see_VB [_NN 1_CD ]_NN )_) ._.
        Pathophysiological_NNP conditions_NNS and_CC pharmacological_JJ
        manipulations_NNS that_WDT affect_VBP central_NN and_CC /_NN or_CC peripheral_JJ nervous_JJ
        system_NN structures_NNS involved_VBN in_IN micturition_NN may_MD alter_VB the_DT
        function_NN of_IN these_DT two_CD organs_NNS [_NN 2_CD ]_NN ._.
        Atypical_NNP antipsychotic_JJ (_( neuroleptic_JJ )_) agents_NNS are_VBP favored_VBN
        over_IN traditional_JJ antipsychotic_JJ medication_NN (_( e_SYM ._. g_SYM ._.
        haloperidol_NN )_) because_IN of_IN their_PRP$ lower_JJR incidence_NN of_IN
        extrapyramidal_NN side_NN effects_NNS ,_, their_PRP$ greater_JJR efficacy_NN in_IN
        improving_VBG negative_JJ symptoms_NNS of_IN schizophrenia_NN ,_, and_CC their_PRP$
        effectiveness_NN in_IN treating_VBG schizophrenic_JJ patients_NNS not_RB
        responding_VBG to_TO conventional_JJ neuroleptics_NNS [_NN 3_CD ]_NN ._. However_RB ,_,
        side_NN effects_NNS continue_VBP to_TO pose_VB a_DT challenge_NN to_TO effective_JJ
        treatment_NN [_NN 4_CD ]_NN ._. These_DT novel_NN neuroleptics_NNS display_VBP a_DT
        complex_JJ pharmacological_JJ profile_NN with_IN affinities_NNS for_IN several_JJ
        receptor_NN systems_NNS but_CC are_VBP generally_RB characterized_VBN by_IN a_DT
        greater_JJR affinity_NN for_IN the_DT 5_CD -_: HT_NNP 2_CD A_DT receptor_NN than_IN for_IN the_DT
        target_NN of_IN the_DT traditional_JJ neuroleptics_NNS ,_, the_DT D_NNP 2_CD receptor_NN [_NN 4_CD
        5_CD ]_NN ._.
        We_PRP have_VBP shown_VBN recently_RB that_IN the_DT atypical_JJ antipsychotic_JJ
        clozapine_NN ,_, and_CC to_TO a_DT lesser_JJR extent_NN haloperidol_NN ,_, markedly_RB
        influenced_VBN several_JJ micturition_NN parameters_NNS in_IN anesthetized_JJ
        rats_NNS [_NN 6_CD ]_NN ._. Clozapine_NNP decreased_VBD the_DT micturition_NN volume_NN
        while_IN increasing_VBG bladder_NN capacity_NN ,_, thus_RB increasing_VBG residual_JJ
        volume_NN [_NN 7_CD ]_NN ._. Moreover_RB ,_, clozapine_NN profoundly_RB depressed_VBD the_DT
        activity_NN of_IN the_DT external_JJ urethral_NN sphincter_NN (_( EUS_NNP )_) ._.
        Clozapine_NNP abolished_VBD the_DT electromyogram_NN (_( EMG_NNP )_) recorded_VBN from_IN
        the_DT EUS_NNP during_IN the_DT rising_VBG phase_NN of_IN a_DT bladder_NN contraction_NN
        before_IN urine_NN is_VBZ voided_VBN (_( similar_JJ to_TO the_DT "_'' guarding_VBG reflex_JJ "_'' [_NN
        8_CD 9_CD ]_NN )_) ._. In_IN addition_NN ,_, clozapine_NN also_RB abolished_VBD the_DT high_JJ
        frequency_NN oscillations_NNS in_IN the_DT bladder_NN pressure_NN and_CC
        accompanying_VBG bursts_NNS in_IN the_DT external_JJ urethral_NN sphincter_NN EMG_NNP ,_,
        that_WDT are_VBP present_JJ during_IN the_DT expulsion_NN phase_NN of_IN the_DT
        micturition_NN profile_NN of_IN the_DT rat_NN [_NN 7_CD ]_NN ._. In_IN the_DT clinical_JJ
        literature_NN ,_, clozapine_NN therapy_NN is_VBZ associated_VBN with_IN a_DT high_JJ
        incidence_NN (_( up_IN to_TO 44_CD %_NN in_IN a_DT recent_JJ study_NN [_NN 10_CD ]_NN )_) of_IN urinary_JJ
        incontinence_NN and_CC enuresis_NNS ._.
        Olanzapine_NNP is_VBZ a_DT newer_JJR atypical_JJ antipsychotic_JJ agent_NN with_IN
        a_DT pharmacological_JJ profile_NN very_RB similar_JJ to_TO that_DT of_IN clozapine_NN
        [_NN 11_CD ]_NN ._. In_IN human_JJ brain_NN tissue_NN ,_, olanzapine_NN displays_NNS very_RB
        high_JJ affinity_NN for_IN the_DT H_NNP 1_CD histamine_NN receptor_NN ,_, high_JJ affinity_NN
        for_IN 5_CD -_: HT_NNP 2_CD A_DT and_CC 5_CD -_: HT_NNP 2_CD C_NNP receptors_NNS [_NN 12_CD ]_NN ._. In_IN addition_NN it_PRP
        also_RB shows_VBZ affinity_NN for_IN D_NNP 2_CD ,_, muscarinic_JJ ,_, and_CC alpha_NN 1_CD
        receptors_NNS ,_, with_IN lower_JJR affinity_NN for_IN alpha_NN 2_CD ,_, 5_CD -_: HT_NNP 1_CD D_NNP and_CC
        5_CD -_: HT_NNP 1_CD A_DT receptors_NNS (_( Table_NNP 1_CD [_NN 12_CD ]_NN )_) ._.
        Olanzapine_NNP therapy_NN is_VBZ associated_VBN with_IN a_DT number_NN of_IN side_NN
        effects_NNS ,_, including_VBG somnolence_NN ,_, agitation_NN ,_, nervousness_NN ,_,
        headaches_NNS ,_, dizziness_NN ,_, weight_NN gain_NN ,_, constipation_NN and_CC dry_JJ
        mouth_NN [_NN 5_CD ]_NN ._. Olanzapine_NNP ,_, however_RB ,_, does_VBZ not_RB produce_VB
        extrapyramidal_NN side_NN effects_NNS ,_, postural_NN hypotension_NN or_CC
        hemotoxicity_NN (_( a_DT particular_NN problem_NN for_IN patients_NNS on_IN
        clozapine_NN therapy_NN [_NN 13_CD ]_NN )_) ._. Although_IN urinary_JJ retention_NN as_IN a_DT
        result_NN of_IN olanzapine_NN therapy_NN may_MD be_VB predicted_VBN from_IN binding_JJ
        studies_NNS due_JJ to_TO olanzapine_NN 's_POS antimuscarinic_JJ activity_NN [_NN 12_CD ]_NN
        only_RB 1_CD case_NN report_NN of_IN micturition_NN disturbance_NN associated_VBN
        with_IN olanzapine_NN has_VBZ recently_RB appeared_VBN [_NN 14_CD ]_NN ._. On_IN the_DT other_JJ
        hand_NN ,_, several_JJ reports_NNS of_IN urinary_JJ disturbances_NNS due_JJ to_TO
        clozapine_NN can_MD be_VB found_VBN in_IN the_DT clinical_JJ literature_NN [_NN 3_CD 10_CD 15_CD
        ]_NN ._.
        Risperidone_NNP ,_, another_DT novel_NN atypical_JJ neuroleptic_JJ ,_, shows_VBZ
        very_RB high_JJ affinity_NN for_IN 5_CD HT-_NNP 2_CD A_DT receptors_NNS with_IN lower_JJR affinity_NN
        for_IN D_NNP 2_CD receptors_NNS ._. In_IN terms_NNS of_IN profile_NN risperidone_NN binds_NNS
        5_CD HT_NNP 2_CD A_DT >_NN >_NN alpha_NN 1_CD =_SYM H_NNP 1_CD >_NN D_NNP 2_CD >_NN alpha_NN 2_CD (_( Table_NNP 1_CD [_NN 12_CD 16_CD ]_NN
        )_) ._. Risperidone_NNP displays_NNS little_JJ or_CC no_DT affinity_NN for_IN the_DT
        muscarinic_JJ receptor_NN [_NN 11_CD 12_CD 16_CD ]_NN and_CC yet_RB risperidone_NN
        therapy_NN has_VBZ been_VBN associated_VBN with_IN urinary_JJ incontinence_NN (_( 28_CD %_NN
        in_IN some_DT cases_NNS [_NN 17_CD 18_CD 19_CD ]_NN )_) ._.
        We_PRP undertook_VBD this_DT study_NN to_TO examine_VB the_DT effects_NNS of_IN
        olanzapine_NN and_CC risperidone_NN on_IN the_DT cystometrogram_NN of_IN
        anesthetized_JJ rats_NNS ._. These_DT two_CD novel_NN atypical_JJ neuroleptic_JJ
        compounds_NNS are_VBP used_VBN in_IN clinical_JJ practice_NN and_CC it_PRP might_MD be_VB
        important_JJ to_TO identify_VB possible_JJ side_NN effects_NNS that_WDT may_MD have_VB
        an_DT impact_NN on_IN compliance_NN to_TO therapy_NN or_CC adversely_RB affect_VB the_DT
        patient_NN 's_POS quality_NN of_IN life_NN (_( e_SYM ._. g_SYM ._. persistent_JJ urinary_JJ
        incontinence_NN )_) ._. Based_VBN on_IN our_PRP$ previous_JJ findings_NNS with_IN
        clozapine_NN ,_, and_CC given_VBN the_DT similarity_NN in_IN pharmacological_JJ
        profiles_NNS between_IN olanzapine_NN and_CC clozapine_NN ,_, we_PRP hypothesized_VBN
        that_DT olanzapine_NN might_MD also_RB result_VB in_IN changes_NNS in_IN urodynamic_JJ
        variables_NNS and_CC /_NN or_CC external_JJ urethral_NN sphincter_NN EMG_NNP ._.
        Risperidone_NNP provides_VBZ an_DT interesting_JJ comparison_NN to_TO
        olanzapine_NN since_IN it_PRP has_VBZ a_DT similar_JJ pharmacological_JJ profile_NN
        to_TO olanzapine_NN but_CC without_IN the_DT antimuscarinic_JJ activity_NN ._. In_IN
        this_DT study_NN olanzapine_NN had_VBD greater_JJR effects_NNS than_IN risperidone_NN
        but_CC both_DT decreased_VBN micturition_NN volume_NN and_CC increased_VBN
        residual_JJ volume_NN in_IN anesthetized_JJ rats_NNS ._. In_IN addition_NN ,_, they_PRP
        inhibited_VBD the_DT activity_NN of_IN the_DT external_JJ urethral_NN sphincter_NN ._.
        Olanzapine_NNP ,_, but_CC not_RB risperidone_NN ,_, also_RB had_VBD peripheral_JJ
        effects_NNS that_WDT reduced_VBD bladder_NN contraction_NN amplitude_NN to_TO
        electrical_JJ stimulation_NN of_IN the_DT pelvic_JJ nerve_NN ._.
      
      
        Results_NNS
        
          Effects_NNPS of_IN olanzapine_NN and_CC risperidone_NN on_IN single_JJ
          cystometry_NN parameters_NNS (_( Tables_NNP 2_CD and_CC 3_LS )_)
          Olanzapine_NNP had_VBD no_DT effect_NN on_IN bladder_NN capacity_NN (_( Fig_NNP 3_CD A_DT )_)
          and_CC risperidone_NN increased_VBD BC_NNP only_RB at_IN the_DT highest_JJS dose_NN (_( 10_CD
          mg_NN /_NN kg_NN ;_: Fig_NNP 2_CD I_PRP ,_, J_NNP ;_: 3_CD A_DT )_) when_WRB the_DT bladder_NN capacity_NN was_VBD 0_CD ._. 54_CD
          ml_NN (_( S_NNP ._. E_NNP ._. M_NNP =_SYM ±_NN 0_CD ._. 08_CD ;_: Table_NNP 3_LS )_) compared_VBN to_TO 0_CD ._. 35_CD ml_NN (_( ±_NN 0_CD ._. 097_CD )_)
          for_IN vehicle-injected_JJ control_NN ._.
          Micturition_NNP volume_NN ,_, however_RB ,_, was_VBD decreased_VBN by_IN both_DT
          olanzapine_NN and_CC risperidone_NN ._. The_DT mean_JJ micturition_NN volume_NN
          in_IN the_DT olanzapine_NN group_NN after_IN administration_NN of_IN vehicle_NN
          was_VBD 0_CD ._. 2_CD ml_NN (_( ±_NN 0_CD ._. 0_CD ._. 37_CD )_) ._. However_RB ,_, after_IN 0_CD ._. 1_CD and_CC 1_CD ._. 0_CD mg_NN /_NN kg_NN
          the_DT micturition_NN volume_NN dropped_VBD to_TO 0_CD ._. 08_CD ml_NN (_( ±_NN 0_CD ._. 014_CD )_) and_CC
          0_CD ._. 04_CD ml_NN (_( ±_NN 0_CD ._. 006_CD )_) ,_, respectively_RB (_( Fig_NNP ._. 3_LS B_NNP ;_: Table_NNP 2_LS )_) ._.
          Similarly_RB ,_, the_DT risperidone_NN group_NN had_VBD a_DT mean_JJ micturition_NN
          volume_NN of_IN 0_CD ._. 27_CD ml_NN (_( ±_NN 0_CD ._. 072_CD )_) after_IN vehicle_NN injection_NN ,_, but_CC
          there_EX was_VBD a_DT significant_JJ decrease_NN to_TO 0_CD ._. 1_CD ml_NN (_( ±_NN 0_CD ._. 019_CD )_) and_CC
          0_CD ._. 12_CD ml_NN (_( ±_NN 0_CD ._. 016_CD )_) after_IN 0_CD ._. 1_CD and_CC 1_CD ._. 0_CD mg_NN /_NN kg_NN of_IN risperidone_NN
          (_( Fig_NNP ._. 3_LS B_NNP ;_: Table_NNP 3_LS )_) ._. At_IN 10_CD mg_NN /_NN kg_NN of_IN risperidone_NN ,_, the_DT
          micturition_NN volume_NN was_VBD 0_CD ._. 19_CD ml_NN (_( ±_NN 0_CD ._. 036_CD )_) which_WDT was_VBD not_RB
          statistically_RB different_JJ from_IN the_DT control_NN values_NNS ._.
          Consequently_RB ,_, the_DT residual_JJ volume_NN showed_VBD significant_JJ
          increases_NNS after_IN 0_CD ._. 1_CD and_CC 1_CD mg_NN /_NN kg_NN doses_NNS of_IN olanzapine_NN (_( 76_CD ±_NN
          5_CD ._. 3_CD and_CC 89_CD ±_NN 2_CD ._. 4_CD %_NN ,_, respectively_RB ;_: Fig_NNP 3_CD C_NNP )_) and_CC after_IN all_DT
          doses_NNS of_IN risperidone_NN (_( maximal_NN effect_NN at_IN 0_CD ._. 1_CD mg_NN /_NN kg_NN ;_: 70_CD ±_NN
          7_CD ._. 8_CD %_NN ;_: Fig_NNP ._. 3_LS C_NNP )_) ._.
          Olanzapine_NNP had_VBD no_DT effect_NN on_IN pressure_NN threshold_NN ;_:
          however_RB ,_, risperidone_NN at_IN 1_CD and_CC 10_CD mg_NN /_NN kg_NN resulted_VBD in_IN a_DT
          significant_JJ increase_NN in_IN the_DT pressure_NN threshold_NN (_( 5_CD ._. 0_CD ±_NN
          1_CD ._. 02_CD and_CC 5_CD ._. 8_CD ±_NN 1_CD ._. 02_CD mm_NN Hg_NNP ,_, respectively_RB ;_: Fig_NNP ._. 4_LS A_DT )_)
          compared_VBN to_TO the_DT value_NN observed_VBD during_IN administration_NN of_IN
          vehicle_NN (_( 2_CD ._. 4_LS ±_NN 0_CD ._. 62_CD mm_NN Hg_NNP )_) ._. The_DT peak_NN pressure_NN during_IN
          contraction_NN was_VBD not_RB changed_JJ by_IN any_DT of_IN the_DT doses_NNS of_IN
          olanzapine_NN tested_VBN in_IN this_DT study_NN (_( Fig_NNP ._. 4_LS B_NNP )_) ._. Interestingly_RB ,_,
          10_CD mg_NN /_NN kg_NN of_IN risperidone_NN showed_VBD a_DT modest_JJ ,_, but_CC
          statistically_RB significant_JJ increase_NN in_IN peak_NN contraction_NN
          pressure_NN (_( 13_CD ._. 7_CD ±_NN 1_CD ._. 34_CD mm_NN Hg_NNP compared_VBD to_TO control_VB value_NN of_IN
          11_CD ._. 5_LS ±_NN 0_CD ._. 95_CD mm_NN Hg_NNP ;_: Fig_NNP ._. 4_LS B_NNP )_) ._.
          The_DT contraction_NN time_NN was_VBD not_RB affected_VBN by_IN either_DT
          olanzapine_NN or_CC risperidone_NN (_( Fig_NNP ._. 5_LS A_DT )_) but_CC the_DT expulsion_NN
          time_NN (_( the_DT time_NN during_IN which_WDT the_DT HFO_NNP occur_VB )_) was_VBD
          significantly_RB decreased_VBN by_IN both_DT (_( Fig_NNP ._. 1_LS ;_: Fig_NNP ._. 2_LS ;_: Fig_NNP ._.
          5_LS B_NNP )_) ._. Olanzapine_NNP decreased_VBD the_DT expulsion_NN time_NN from_IN 2_CD ._. 6_CD
          (_( ±_NN 0_CD ._. 55_CD )_) sec_NN after_IN vehicle_NN injection_NN to_TO 0_CD ._. 9_CD (_( ±_NN 0_CD ._. 38_CD )_) and_CC 0_CD
          sec_NN after_IN 0_CD ._. 1_CD and_CC 1_CD ._. 0_CD mg_NN /_NN kg_NN ,_, respectively_RB (_( Fig_NNP ._. 5_LS B_NNP )_) ._. The_DT
          risperidone_NN group_NN had_VBD an_DT expulsion_NN time_NN of_IN 3_CD ._. 6_CD (_( ±_NN 0_CD ._. 83_CD )_)
          sec_NN after_IN control_NN and_CC it_PRP decreased_VBD to_TO 1_CD ._. 5_CD (_( ±_NN 0_CD ._. 34_CD )_) and_CC 1_CD ._. 4_CD
          (_( ±_NN 0_CD ._. 35_CD )_) sec_NN after_IN 0_CD ._. 1_CD and_CC 1_CD mg_NN /_NN kg_NN of_IN risperidone_NN (_( Fig_NNP
          5_CD B_NNP )_) ._. At_IN 10_CD mg_NN /_NN kg_NN of_IN risperidone_NN ,_, the_DT expulsion_NN time_NN was_VBD
          2_CD ._. 2_CD (_( ±_NN 0_CD ._. 46_CD )_) sec_NN ._.
          Similarly_RB ,_, olanzapine_NN significantly_RB decreased_VBD the_DT
          amplitude_NN of_IN high_JJ frequency_NN oscillations_NNS (_( HFO_NNP )_) from_IN a_DT
          control_NN value_NN of_IN 1_CD ._. 6_CD (_( ±_NN 0_CD ._. 19_CD )_) to_TO 1_CD ._. 0_CD (_( ±_NN 0_CD ._. 38_CD )_) mm_NN Hg_NNP at_IN 0_CD ._. 1_CD
          mg_NN /_NN kg_NN and_CC abolished_VBD the_DT HFO_NNP in_IN all_DT animals_NNS tested_VBN at_IN 1_CD
          mg_NN /_NN kg_NN (_( Fig_NNP ._. 1_LS ;_: 5_CD C_NNP )_) ._. Risperidone_NNP also_RB reduced_VBD the_DT
          amplitude_NN of_IN the_DT HFO_NNP from_IN 1_CD ._. 6_CD (_( ±_NN 0_CD ._. 19_CD )_) to_TO 1_CD ._. 0_CD (_( ±_NN 0_CD ._. 22_CD )_) ,_, 0_CD ._. 9_CD
          (_( ±_NN 0_CD ._. 18_CD )_) and_CC 1_CD ._. 1_CD (_( ±_NN 0_CD ._. 22_CD )_) mm_NN Hg_NNP after_IN 0_CD ._. 1_CD ,_, 1_CD and_CC 10_CD mg_NN /_NN kg_NN
          of_IN risperidone_NN (_( Fig_NNP ._. 2_LS ;_: 5_CD C_NNP )_) ._.
        
        
          Effects_NNPS of_IN olanzapine_NN and_CC risperidone_NN on_IN the_DT
          external_JJ urethral_NN sphincter_NN (_( Tables_NNP 2_CD and_CC 3_LS )_)
          The_DT EMG_NNP recorded_VBD from_IN the_DT urethral_NN sphincter_NN during_IN
          bladder_NN contractions_NNS also_RB showed_VBD changes_NNS after_IN
          risperidone_NN or_CC olanzapine_NN ._. Phase_NN 1_CD of_IN the_DT EMG_NNP ,_, occurring_VBG
          during_IN the_DT initial_JJ rise_NN in_IN bladder_NN pressure_NN during_IN a_DT
          contraction_NN ,_, was_VBD significantly_RB decreased_VBN by_IN olanzapine_NN at_IN
          0_CD ._. 1_CD and_CC 1_CD mg_NN /_NN kg_NN to_TO 76_CD (_( ±_NN 1_CD ._. 9_CD )_) and_CC 47_CD (_( ±_NN 6_CD ._. 0_CD )_) percent_NN of_IN the_DT
          control_NN value_NN (_( Fig_NNP ._. 1_LS F_NN ;_: 1_CD H_NNP ;_: 6_CD A_DT )_) ._. However_RB ,_, risperidone_NN had_VBD
          no_DT significant_JJ effect_NN on_IN the_DT EMG_NNP during_IN phase_NN 1_CD (_( Fig_NNP
          6_CD A_DT )_) ._.
          Phase_NN 2_CD ,_, which_WDT corresponds_NNS to_TO the_DT occurrence_NN of_IN high_JJ
          frequency_NN oscillations_NNS ,_, showed_VBD significant_JJ decreases_NNS in_IN
          the_DT integrated_VBN EMG_NNP following_VBG olanzapine_NN or_CC risperidone_NN
          administration_NN ._. 0_CD ._. 1_CD mg_NN /_NN kg_NN of_IN olanzapine_NN significantly_RB
          decreased_VBD the_DT overall_JJ EMG_NNP during_IN this_DT phase_NN to_TO 42_CD
          (_( ±_NN 11_CD ._. 4_LS )_) %_NN of_IN the_DT control_NN value_NN ,_, and_CC 1_CD ._. 0_CD mg_NN /_NN kg_NN of_IN
          olanzapine_NN abolished_VBD the_DT bursting_VBG pattern_NN of_IN EMG_NNP (_( Fig_NNP
          1_CD G_NNP ;_: 1_CD H_NNP ;_: Fig_NNP 6_CD B_NNP )_) ._. While_IN risperidone_NN also_RB decreased_VBD the_DT
          Phase_NN 2_CD EMG_NNP ,_, the_DT maximal_NN decrease_NN was_VBD 47_CD (_( ±_NN 12_CD ._. 7_CD )_) %_NN at_IN 1_CD ._. 0_CD
          mg_NN /_NN kg_NN when_WRB compared_VBN to_TO control_VB (_( Fig_NNP 6_CD B_NNP )_) and_CC the_DT bursting_VBG
          pattern_NN was_VBD not_RB abolished_VBN ._. At_IN 10_CD mg_NN /_NN kg_NN of_IN risperidone_NN ,_,
          the_DT phase_NN 2_CD EMG_NNP was_VBD 71_CD (_( ±_NN 22_CD )_) %_NN and_CC was_VBD not_RB significantly_RB
          different_JJ from_IN vehicle_NN ._.
          Phase_NN 3_CD of_IN the_DT EMG_NNP during_IN a_DT bladder_NN contraction_NN also_RB
          showed_VBD significant_JJ changes_NNS following_VBG olanzapine_NN or_CC
          risperidone_NN (_( Fig_NNP 6_CD C_NNP )_) ._. Both_DT drugs_NNS significantly_RB decreased_VBD
          the_DT amount_NN of_IN integrated_VBN EMG_NNP but_CC 0_CD ._. 1_CD mg_NN /_NN kg_NN olanzapine_NN had_VBD
          a_DT more_RBR profound_JJ effect_NN (_( Fig_NNP 6_CD C_NNP )_) ,_, reducing_VBG the_DT EMG_NNP to_TO 35_CD
          (_( ±_NN 5_CD ._. 2_LS )_) %_NN of_IN the_DT control_NN value_NN at_IN 1_CD ._. 0_CD mg_NN /_NN kg_NN compared_VBN to_TO 68_CD
          (_( ±_NN 8_CD ._. 0_CD )_) %_NN of_IN control_NN after_IN a_DT similar_JJ dose_NN of_IN risperidone_NN ._.
          At_IN 10_CD mg_NN /_NN kg_NN of_IN risperidone_NN the_DT EMG_NNP was_VBD 73_CD (_( ±_NN 9_CD ._. 0_CD )_) %_NN of_IN
          vehicle_NN ._.
          Finally_RB ,_, while_IN risperidone_NN had_VBD no_DT effect_NN on_IN the_DT
          amplitude_NN of_IN the_DT EMG_NNP bursts_NNS occurring_VBG the_DT expulsion_NN phase_NN
          (_( Fig_NNP 1_CD ;_: Fig_NNP 6_CD D_NNP )_) ,_, olanzapine_NN abolished_VBD bursting_VBG of_IN the_DT EMG_NNP
          at_IN 1_CD ._. 0_CD mg_NN /_NN kg_NN in_IN all_DT animals_NNS tested_VBN (_( Fig_NNP 1_CD H_NNP ;_: 6_CD D_NNP )_) ._.
        
        
          Effects_NNPS of_IN olanzapine_NN and_CC risperidone_NN on_IN blood_NN
          pressure_NN
          Both_DT olanzapine_NN and_CC risperidone_NN decreased_VBD mean_VB
          arterial_NN pressure_NN (_( MAP_NNP )_) in_IN anesthetized_JJ rats_NNS (_( Fig_NNP ._. 7_CD )_) ._.
          Risperidone_NNP produced_VBD significant_JJ effects_NNS at_IN all_PDT the_DT doses_NNS
          tested_VBN ,_, with_IN a_DT maximum_NN drop_NN in_IN MAP_NNP of_IN approximately_RB 46_CD mm_NN
          Hg_NNP at_IN 1_CD mg_NN /_NN kg_NN (_( Mean_VB =_SYM 44_CD mm_NN Hg_NNP ;_: SEM_NNP ±_NN 1_CD ._. 37_CD )_) ._. Olanzapine_NNP
          showed_VBD a_DT significant_JJ decrease_NN in_IN MAP_NNP at_IN 1_CD ._. 0_CD mg_NN /_NN kg_NN with_IN a_DT
          maximum_NN drop_NN of_IN approximately_RB 26_CD mm_NN Hg_NNP (_( Mean_VB =_SYM 55_CD ±_NN 3_CD ._. 76_CD
          mm_NN Hg_NNP )_) ._. In_IN two_CD animals_NNS where_WRB olanzapine_NN was_VBD administered_VBN
          at_IN 10_CD mg_NN /_NN kg_NN ,_, there_EX was_VBD no_DT further_JJ reduction_NN in_IN MAP_NNP (_( Mean_VB
          =_SYM 57_CD ±_NN 4_CD ._. 95_CD mm_NN Hg_NNP )_) ,_, however_RB ,_, significant_JJ respiratory_JJ
          depression_NN was_VBD observed_VBN and_CC therefore_RB we_PRP excluded_VBD this_DT
          dose_NN for_IN the_DT remaining_VBG animals_NNS receiving_VBG olanzapine_NN ._.
        
        
          Effects_NNPS of_IN olanzapine_NN and_CC risperidone_NN on_IN bladder_NN
          contractions_NNS elicited_JJ by_IN electrical_JJ stimulation_NN of_IN the_DT
          pelvic_JJ nerve_NN
          Prolonged_NNP electrical_JJ stimulation_NN of_IN the_DT pelvic_JJ nerve_NN
          elicits_NNS a_DT sustained_VBN bladder_NN contraction_NN with_IN two_CD
          components_NNS ._. An_DT initial_JJ rise_NN in_IN bladder_NN pressure_NN (_( Phase_NN I_PRP ;_:
          Fig_NNP ._. 8_CD A_DT )_) that_WDT is_VBZ resistant_JJ to_TO muscarinic_JJ blockade_NN and_CC a_DT
          sustained_VBN part_NN of_IN the_DT contraction_NN (_( Phase_NN II_NNP or_CC plateau_NN
          phase_NN )_) that_WDT is_VBZ very_RB sensitive_JJ to_TO anti-muscarinic_JJ agents_NNS [_NN
          20_CD 21_CD ]_NN ._. Olanzapine_NNP at_IN 1_CD and_CC 10_CD mg_NN /_NN kg_NN reduced_VBD the_DT
          amplitude_NN of_IN Phase_NN I_PRP to_TO 79_CD and_CC 74_CD %_NN of_IN the_DT control_NN values_NNS ,_,
          respectively_RB (_( Fig_NNP ._. 8_CD A_DT ;_: B_NNP )_) ._. Risperidone_NNP ,_, on_IN the_DT other_JJ hand_NN ,_,
          significantly_RB increased_VBD the_DT amplitude_NN of_IN phase_NN I_PRP after_IN 10_CD
          mg_NN /_NN kg_NN (_( 116_CD %_NN of_IN control_NN )_) ._.
          The_DT plateau_NN phase_NN ,_, or_CC phase_NN II_NNP of_IN the_DT pelvic_JJ nerve_NN
          induced_VBD bladder_NN contraction_NN was_VBD significantly_RB reduced_VBN by_IN
          olanzapine_NN (_( Fig_NNP ._. 8_CD A_DT ;_: 6_CD C_NNP )_) ._. At_IN 1_CD and_CC 10_CD mg_NN /_NN kg_NN ,_, the_DT response_NN
          was_VBD 47_CD and_CC 33_CD %_NN of_IN the_DT control_NN values_NNS ,_, respectively_RB ._.
          Risperidone_NNP had_VBD no_DT effect_NN on_IN Phase_NN II_NNP amplitude_NN (_( Fig_NNP ._. 8_CD A_DT ;_:
          8_CD C_NNP )_) ._.
        
      
      
        Discussion_NNP
        
          Effects_NNPS of_IN olanzapine_NN and_CC risperidone_NN on_IN urodynamic_JJ
          parameters_NNS and_CC the_DT external_JJ sphincter_NN EMG_NNP
          Both_DT olanzapine_NN and_CC risperidone_NN are_VBP compounds_NNS with_IN
          relatively_RB high_JJ oral_JJ bioavailability_NN ._. Clinically_NNP
          effective_JJ doses_NNS of_IN olanzapine_NN (_( 10_CD -_: 15_CD mg_NN /_NN day_NN ;_: 18_CD ._. 4_LS -_: 30_CD ._. 6_CD
          ng_NN /_NN ml_NN plasma_NN concentration_NN [_NN 22_CD 23_CD 24_CD ]_NN )_) or_CC risperidone_NN
          (_( 3_CD -_: 6_CD mg_NN /_NN day_NN ;_: 15_CD -_: 30_CD ._. 8_CD ng_NN /_NN ml_NN combined_VBD plasma_NN concentration_NN
          of_IN risperidone_NN and_CC 9_CD -_: hydroxy-risperidone_JJ [_NN 25_CD ]_NN )_)
          correspond_VB well_RB with_IN the_DT dose_NN of_IN 1_CD ._. 0_CD mg_NN /_NN kg_NN (_( equivalent_JJ to_TO
          12_CD ._. 5_LS ng_NN /_NN ml_NN )_) in_IN the_DT present_JJ study_NN ._.
          Both_DT neuroleptics_NNS markedly_RB decreased_VBD the_DT micturition_NN
          volume_NN ,_, expulsion_NN time_NN ,_, and_CC amplitude_NN of_IN the_DT HFO_NNP while_IN
          residual_JJ volume_NN increased_VBD ._. Most_JJS of_IN the_DT effects_NNS of_IN either_DT
          neuroleptic_JJ occurred_VBD at_IN doses_NNS of_IN 0_CD ._. 1_CD and_CC 1_CD ._. 0_CD mg_NN /_NN kg_NN ._.
          Olanzapine_NNP appeared_VBD to_TO have_VB a_DT greater_JJR maximal_NN effect_NN than_IN
          risperidone_NN ._. At_IN the_DT highest_JJS dose_NN of_IN risperidone_NN (_( 10_CD
          mg_NN /_NN kg_NN )_) there_EX was_VBD less_JJR of_IN an_DT effect_NN for_IN the_DT urodynamic_JJ
          parameters_NNS mentioned_VBN above_IN ._. This_DT is_VBZ an_DT interesting_JJ
          observation_NN that_WDT was_VBD not_RB explored_JJ further_RB in_IN the_DT present_JJ
          study_NN ._. The_DT physiological_JJ significance_NN is_VBZ unclear_JJ since_IN
          the_DT 10_CD mg_NN /_NN kg_NN dose_NN is_VBZ well_RB above_IN the_DT clinically_RB effective_JJ
          doses_NNS of_IN risperidone_NN ._.
          Olanzapine_NNP did_VBD not_RB have_VB an_DT effect_NN on_IN bladder_NN capacity_NN
          or_CC pressure_NN threshold_NN while_IN risperidone_NN increased_VBN both_DT
          although_IN only_RB at_IN the_DT highest_JJS doses_NNS ._. Clozapine_NNP ,_, on_IN the_DT
          other_JJ hand_NN ,_, was_VBD observed_VBN previously_RB to_TO increase_VB bladder_NN
          capacity_NN and_CC pressure_NN threshold_NN [_NN 6_CD 7_CD ]_NN ._. Olanzapine_NNP had_VBD
          no_DT effect_NN on_IN bladder_NN peak_NN pressure_NN during_IN contraction_NN and_CC
          only_RB the_DT highest_JJS dose_NN of_IN risperidone_NN showed_VBD an_DT increase_NN
          in_IN pressure_NN (_( 119_CD %_NN of_IN control_NN )_) ._. The_DT increase_NN in_IN pressure_NN
          after_IN the_DT highest_JJS dose_NN of_IN risperidone_NN was_VBD interesting_JJ and_CC
          was_VBD also_RB observed_VBN following_VBG electrical_JJ stimulation_NN of_IN the_DT
          pelvic_JJ nerve_NN suggesting_VBG a_DT possible_JJ peripheral_JJ
          mechanism_NN ._.
          Olanzapine_NNP ,_, but_CC not_RB risperidone_NN ,_, decreased_VBD the_DT
          integrated_VBN EMG_NNP recorded_VBD during_IN the_DT beginning_NN of_IN a_DT bladder_NN
          contraction_NN (_( Phase_NN 1_CD ;_: comparable_JJ to_TO the_DT guarding_VBG reflex_JJ )_) ._.
          Both_DT neuroleptics_NNS decreased_VBD the_DT EMG_NNP during_IN phase_NN 2_CD ,_, where_WRB
          high_JJ frequency_NN oscillations_NNS occur_VBP in_IN the_DT bladder_NN pressure_NN
          along_IN with_IN bursting_VBG in_IN the_DT EUS_NNP ,_, with_IN the_DT highest_JJS dose_NN of_IN
          olanzapine_NN (_( 1_CD ._. 0_CD mg_NN /_NN kg_NN )_) abolishing_VBG the_DT HFO_NNP and_CC the_DT
          bursting_VBG pattern_NN ._. The_DT integrated_VBN EMG_NNP recorded_VBD during_IN the_DT
          end_NN of_IN the_DT bladder_NN contraction_NN (_( Phase_NN 3_LS )_) was_VBD also_RB
          decreased_VBN by_IN both_DT neuroleptics_NNS ,_, with_IN olanzapine_NN reducing_VBG
          it_PRP to_TO 69_CD %_NN and_CC 35_CD %_NN at_IN 0_CD ._. 1_CD and_CC 1_CD ._. 0_CD mg_NN /_NN kg_NN ,_, respectively_RB ,_,
          whereas_IN the_DT maximal_NN effect_NN for_IN risperidone_NN was_VBD observed_VBN
          at_IN 1_CD mg_NN /_NN kg_NN (_( 68_CD %_NN )_) ._.
          Finally_RB ,_, neither_DT neuroleptic_JJ decreased_VBD the_DT amplitude_NN
          of_IN the_DT individual_JJ bursts_NNS of_IN EMG_NNP recorded_VBD during_IN phase_NN 2_CD ,_,
          except_IN for_IN the_DT largest_JJS dose_NN of_IN olanzapine_NN (_( 1_CD mg_NN /_NN kg_NN )_) that_WDT
          abolished_VBD the_DT bursting_VBG pattern_NN ._.
          Therefore_RB ,_, as_IN was_VBD the_DT case_NN for_IN urodynamic_JJ parameters_NNS ,_,
          although_IN both_DT neuroleptics_NNS decreased_VBD the_DT activity_NN of_IN the_DT
          external_JJ urethral_NN sphincter_NN (_( as_IN reflected_VBN in_IN the_DT
          integrated_VBN EMG_NNP )_) ,_, it_PRP appears_VBZ that_IN the_DT effects_NNS of_IN
          olanzapine_NN were_VBD greater_JJR than_IN those_DT of_IN risperidone_NN ._. As_IN was_VBD
          the_DT case_NN for_IN some_DT urodynamic_JJ parameters_NNS ,_, the_DT highest_JJS dose_NN
          of_IN risperidone_NN showed_VBD a_DT parabolic_JJ effect_NN for_IN some_DT of_IN the_DT
          EMG_NNP parameters_NNS ._.
          Blockade_NNP of_IN the_DT external_JJ urethral_NN sphincter_NN in_IN
          anesthetized_JJ rats_NNS results_NNS in_IN a_DT disappearance_NN of_IN the_DT HFO_NNP
          from_IN the_DT bladder_NN pressure_NN recording_NN as_RB well_RB as_IN a_DT
          disappearance_NN of_IN the_DT bursting_VBG pattern_NN of_IN the_DT EUS_NNP EMG_NNP
          observed_VBD during_IN HFO_NNP [_NN 26_CD 27_CD 28_CD ]_NN ._. In_IN addition_NN ,_, there_EX is_VBZ
          a_DT decreased_VBN ability_NN of_IN the_DT bladder_NN to_TO empty_VB as_IN evidenced_VBN
          by_IN a_DT decreased_VBN micturition_NN volume_NN and_CC an_DT increased_VBN
          residual_JJ volume_NN [_NN 26_CD 27_CD 29_CD ]_NN ._. Therefore_RB ,_, inhibition_NN of_IN
          the_DT external_JJ urethral_NN sphincter_NN ,_, as_IN was_VBD the_DT case_NN for_IN the_DT
          two_CD neuroleptics_NNS in_IN the_DT present_JJ study_NN and_CC also_RB for_IN
          clozapine_NN in_IN our_PRP$ earlier_JJR study_NN [_NN 7_CD ]_NN ,_, might_MD provide_VB an_DT
          important_JJ mechanism_NN by_IN which_WDT the_DT bladder_NN is_VBZ rendered_VBN less_RBR
          effective_JJ in_IN emptying_VBG and_CC therefore_RB altering_VBG other_JJ
          urodynamic_JJ variables_NNS resulting_VBG in_IN decreased_VBD micturition_NN
          volume_NN and_CC increased_VBN residual_JJ volume_NN in_IN rats_NNS ._.
        
        
          Possible_JJ neuropharmacological_JJ mechanisms_NNS for_IN the_DT
          effect_NN of_IN olanzapine_NN and_CC risperidone_NN on_IN the_DT lower_JJR urinary_JJ
          tract_NN
          We_PRP tested_VBD for_IN peripheral_JJ antimuscarinic_JJ actions_NNS of_IN
          both_DT neuroleptics_NNS by_IN examining_VBG their_PRP$ effects_NNS on_IN bladder_NN
          contractions_NNS elicited_JJ by_IN electrical_JJ stimulation_NN of_IN the_DT
          pelvic_JJ nerve_NN ._. In_IN this_DT preparation_NN ,_, olanzapine_NN but_CC not_RB
          risperidone_NN reduced_VBD the_DT initial_JJ contraction_NN amplitude_NN
          (_( Phase_NN I_PRP )_) somewhat_RB and_CC markedly_RB depressed_VBD the_DT prolonged_JJ
          contraction_NN phase_NN (_( Phase_NN II_NNP ;_: Fig_NNP ._. 8_CD )_) that_WDT is_VBZ thought_VBN to_TO
          be_VB mediated_JJ by_IN muscarinic_JJ receptors_NNS [_NN 20_CD 21_CD ]_NN ._. During_IN
          cystometry_NN ,_, however_RB ,_, neither_DT olanzapine_NN nor_CC risperidone_NN
          affected_VBD the_DT peak_NN pressure_NN during_IN bladder_NN contraction_NN ._.
          Therefore_RB ,_, although_IN olanzapine_NN had_VBD a_DT peripheral_JJ effect_NN on_IN
          bladder_NN contraction_NN amplitude_NN ,_, as_IN might_MD be_VB expected_VBN from_IN
          its_PRP$ antimuscarinic_JJ effects_NNS ,_, this_DT effect_NN is_VBZ not_RB reflected_VBN
          in_IN the_DT peak_NN contraction_NN pressures_NNS observed_VBD during_IN
          cystometry_NN ._. This_DT discrepancy_NN is_VBZ probably_RB due_JJ to_TO the_DT fact_NN
          that_IN during_IN a_DT bladder_NN contraction_NN against_IN a_DT closed_VBN outlet_NN
          (_( electrical_JJ stimulation_NN of_IN the_DT pelvic_JJ nerve_NN )_) higher_JJR
          pressures_NNS were_VBD developed_VBN than_IN were_VBD observed_VBN during_IN
          cystometry_NN when_WRB the_DT outlet_NN was_VBD not_RB obstructed_VBN ._. Since_IN the_DT
          clinically_RB effective_JJ dose_NN of_IN olanzapine_NN (_( 10_CD -_: 15_CD mg_NN /_NN day_NN ;_:
          18_CD ._. 4_LS -_: 30_CD ._. 6_CD ng_NN /_NN ml_NN plasma_NN concentration_NN [_NN 22_CD 23_CD 24_CD ]_NN )_) is_VBZ
          greater_JJR than_IN the_DT first_JJ dose_NN observed_VBD to_TO produce_VB
          significant_JJ peripheral_JJ antimuscarinic_JJ effects_NNS in_IN this_DT
          study_NN (_( 1_CD ._. 0_CD mg_NN /_NN kg_NN ;_: equivalent_JJ to_TO 12_CD ._. 5_LS ng_NN /_NN ml_NN plasma_NN
          concentration_NN )_) a_DT possible_JJ peripheral_JJ anti-muscarinic_JJ on_IN
          the_DT bladder_NN during_IN olanzapine_NN therapy_NN remains_VBZ a_DT
          concern_NN ._.
          Muscarinic_NNP blockade_NN with_IN atropine_NN decreased_VBD
          micturition_NN pressure_NN and_CC micturition_NN volume_NN ,_, while_IN
          increasing_VBG residual_JJ volume_NN [_NN 30_CD ]_NN and_CC bladder_NN capacity_NN [_NN
          31_CD ]_NN ._. Similarly_RB ,_, central_JJ administration_NN of_IN atropine_NN
          decreased_VBD peak_NN pressure_NN and_CC voiding_VBG efficiency_NN while_IN
          increasing_VBG bladder_NN capacity_NN in_IN awake_JJ rats_NNS [_NN 32_CD ]_NN ._. Thus_RB
          it_PRP is_VBZ possible_JJ that_IN central_NN and_CC /_NN or_CC peripheral_JJ muscarinic_JJ
          blockade_NN by_IN olanzapine_NN may_MD have_VB contributed_VBN to_TO some_DT of_IN
          the_DT changes_NNS observed_VBD in_IN these_DT parameters_NNS in_IN the_DT present_JJ
          study_NN ._.
          Muscarinic_NNP blockade_NN was_VBD also_RB reported_VBN to_TO decrease_VB the_DT
          EUS_NNP EMG_NNP in_IN all_DT phases_NNS of_IN the_DT bladder_NN contraction_NN [_NN 33_CD ]_NN ._.
          However_RB ,_, another_DT study_NN showed_VBD no_DT effect_NN on_IN the_DT EUS_NNP EMG_NNP
          following_VBG muscarinic_JJ antagonism_NN [_NN 34_CD ]_NN ._. Therefore_RB ,_, the_DT
          exact_JJ role_NN of_IN muscarinic_JJ blockade_NN on_IN the_DT activity_NN of_IN the_DT
          EUS_NNP in_IN the_DT rat_NN is_VBZ unclear_JJ ._.
          It_PRP is_VBZ tempting_JJ to_TO propose_VB that_IN the_DT greater_JJR effect_NN of_IN
          olanzapine_NN on_IN the_DT EUS_NNP may_MD be_VB due_JJ to_TO its_PRP$ antimuscarinic_JJ
          activity_NN ,_, which_WDT risperidone_NN does_VBZ not_RB have_VB ._. In_IN fact_NN ,_,
          clozapine_NN has_VBZ a_DT greater_JJR affinity_NN for_IN muscarinic_JJ receptors_NNS
          than_IN olanzapine_NN [_NN 11_CD ]_NN and_CC clozapine_NN was_VBD also_RB able_JJ to_TO
          decrease_VB the_DT EMG_NNP and_CC abolish_VB the_DT bursting_VBG pattern_NN during_IN
          phase_NN 2_CD ._.
          Whether_IN muscarinic_JJ blockade_NN affects_VBZ the_DT activity_NN of_IN
          the_DT EUS_NNP by_IN acting_VBG on_IN central_JJ or_CC peripheral_JJ sites_NNS remains_VBZ
          to_TO be_VB determined_VBN ._. A_DT direct_JJ inhibitory_NN action_NN of_IN
          olanzapine_NN on_IN the_DT EUS_NNP muscle_NN itself_PRP is_VBZ not_RB expected_VBN and_CC
          was_VBD not_RB seen_VBN with_IN clozapine_NN [_NN 7_CD ]_NN ._. However_RB ,_,
          antimuscarinic_JJ effects_NNS alone_RB cannot_NN account_NN for_IN all_DT of_IN
          the_DT effects_NNS of_IN olanzapine_NN on_IN the_DT EUS_NNP ,_, since_IN risperidone_NN
          had_VBD a_DT similar_JJ effect_NN although_IN not_RB quite_RB as_IN pronounced_VBN and_CC
          risperidone_NN has_VBZ little_JJ or_CC no_DT affinity_NN for_IN muscarinic_JJ
          receptors_NNS [_NN 16_CD ]_NN ._. Therefore_RB ,_, antagonism_NN of_IN other_JJ
          transmitter_NN systems_NNS ,_, e_SYM ._. g_SYM ._. D_NNP 2_CD ,_, alpha_NN 1_CD ,_, 5_CD -_: HT_NNP 2_CD ,_, remains_VBZ as_IN
          an_DT explanation_NN of_IN the_DT effects_NNS of_IN these_DT neuroleptics_NNS on_IN
          urodynamic_JJ variables_NNS [_NN 6_CD ]_NN ._.
          Selective_NNP antagonism_NN of_IN D_NNP 2_CD receptors_NNS only_RB modestly_RB
          reduced_VBD the_DT amplitude_NN of_IN HFO_NNP without_IN affecting_VBG any_DT other_JJ
          urodynamic_JJ parameters_NNS [_NN 6_CD 35_CD ]_NN ._. Therefore_RB ,_, it_PRP is_VBZ
          possible_JJ that_DT olanzapine_NN and_CC risperidone_NN decrease_VBP the_DT
          amplitude_NN of_IN the_DT HFO_NNP ,_, at_IN least_JJS partly_RB ,_, through_IN antagonism_NN
          of_IN D_NNP 2_CD receptors_NNS ._.
          In_IN anesthetized_JJ rats_NNS ,_, doxazosin_NN (_( alpha_NN 1_CD adrenergic_JJ
          receptor_NN antagonist_NN )_) administered_VBN systemically_RB ,_, increased_VBN
          micturition_NN volume_NN ,_, bladder_NN capacity_NN ,_, residual_JJ volume_NN and_CC
          micturition_NN frequency_NN while_IN decreasing_VBG peak_NN pressure_NN [_NN 36_CD
          ]_NN ._. Only_RB an_DT increase_NN in_IN the_DT micturition_NN frequency_NN was_VBD
          observed_VBN after_IN spinal_JJ administration_NN of_IN doxazosin_NN [_NN 37_CD ]_NN
          ._. Both_DT olanzapine_NN and_CC risperidone_NN have_VBP moderate_JJ affinity_NN
          for_IN the_DT alpha_NN 1_CD adrenergic_JJ receptor_NN (_( Table_NNP 1_LS )_) ,_, therefore_RB
          it_PRP is_VBZ possible_JJ that_IN some_DT of_IN the_DT effects_NNS observed_VBD in_IN the_DT
          present_JJ study_NN were_VBD due_JJ to_TO central_NN and_CC /_NN or_CC peripheral_JJ
          antagonism_NN of_IN alpha_NN 1_CD adrenergic_JJ receptors_NNS by_IN these_DT
          drugs_NNS ._. The_DT decreases_NNS observed_VBD in_IN MAP_NNP suggest_VBP a_DT possible_JJ
          peripheral_JJ alpha_NN 1_CD effect_NN ._. However_RB ,_, we_PRP did_VBD not_RB observe_VB a_DT
          decrease_NN in_IN the_DT peak_NN pressure_NN as_IN would_MD have_VB been_VBN
          predicted_VBN from_IN previous_JJ studies_NNS using_VBG selective_JJ alpha_NN 1_CD
          antagonism_NN [_NN 36_CD ]_NN ._. In_IN addition_NN ,_, bladder_NN capacity_NN was_VBD not_RB
          affected_VBN except_IN at_IN the_DT highest_JJS dose_NN of_IN risperidone_NN
          tested_VBN ._. Urinary_NNP incontinence_NN as_IN a_DT result_NN of_IN olanzapine_NN [_NN
          12_CD ]_NN or_CC clozapine_NN [_NN 15_CD ]_NN therapy_NN was_VBD treated_VBN effectively_RB
          with_IN ephedrine_NN (_( alpha_NN adrenergic_JJ receptor_NN agonist_NN )_) ,_,
          suggesting_VBG a_DT possible_JJ alpha_NN 1_CD effect_NN ._. However_RB ,_,
          alpha_NN 1_CD a-adrenoceptor_JJ gene_NN polymorphism_NN was_VBD found_VBN to_TO play_VB
          no_DT role_NN in_IN clozapine-induced_JJ urinary_JJ incontinence_NN [_NN 38_CD ]_NN
          ._.
          In_IN terms_NNS of_IN the_DT effects_NNS on_IN the_DT EUS_NNP ,_, alpha_NN 1_CD
          antagonists_NNS have_VBP been_VBN shown_VBN to_TO inhibit_VB the_DT EUS_NNP in_IN the_DT cat_NN
          [_NN 39_CD 40_CD 41_CD ]_NN but_CC not_RB in_IN the_DT anesthetized_JJ rat_NN [_NN 42_CD ]_NN ._.
          Finally_RB ,_, both_DT olanzapine_NN and_CC risperidone_NN posses_NNS
          affinities_NNS to_TO several_JJ serotonin_NN receptor_NN subtypes_NNS (_( Table_NNP
          1_LS )_) ._. In_IN cats_NNS ,_, serotonin_NN antagonists_NNS caused_VBD a_DT decrease_NN in_IN
          bladder_NN capacity_NN [_NN 43_CD ]_NN however_RB in_IN anesthetized_JJ rats_NNS ,_,
          serotonin_NN antagonism_NN did_VBD not_RB have_VB an_DT effect_NN on_IN
          micturition_NN [_NN 44_CD ]_NN ._. Recently_RB ,_, a_DT selective_JJ 5_CD -_: HT_NNP 1_CD A_DT
          receptor_NN antagonist_NN (_( WAY-_NNP 100635_CD )_) was_VBD reported_VBN to_TO inhibit_VB
          bladder_NN contractions_NNS in_IN rats_NNS [_NN 45_CD ]_NN yet_RB another_DT report_NN
          only_RB observed_VBD an_DT increase_NN in_IN the_DT pressure_NN threshold_NN [_NN 46_CD
          ]_NN ._. Olanzapine_NNP and_CC risperidone_NN have_VBP only_RB low_JJ to_TO modest_JJ
          affinity_NN for_IN the_DT 5_CD -_: HT_NNP 1_CD A_DT receptor_NN ,_, and_CC higher_JJR affinities_NNS
          for_IN the_DT 5_CD -_: HT_NNP 2_CD A_DT and_CC 5_CD -_: HT_NNP 2_CD C_NNP receptors_NNS [_NN 11_CD 12_CD ]_NN ._. Serotonin_NNP
          5_CD -_: HT_NNP 2_CD and_CC 5_CD -_: HT_NNP 3_CD receptors_NNS facilitate_VBP pudendal_NN reflexes_NNS in_IN
          the_DT cat_NN [_NN 47_CD 48_CD ]_NN ,_, therefore_RB it_PRP is_VBZ possible_JJ that_DT
          antagonism_NN of_IN these_DT receptors_NNS may_MD block_VB the_DT EUS_NNP in_IN the_DT
          anesthetized_JJ rat_NN ._. Given_VBN the_DT modest_JJ role_NN of_IN serotonin_NN
          receptors_NNS in_IN micturition_NN in_IN anesthetized_JJ rats_NNS ,_, it_PRP remains_VBZ
          to_TO be_VB determined_VBN whether_IN the_DT effects_NNS observed_VBD here_RB were_VBD
          due_JJ to_TO anti-serotonergic_JJ effects_NNS of_IN these_DT
          neuroleptics_NNS ._.
        
        
          Clinical_NNP implications_NNS
          While_IN there_EX are_VBP several_JJ reports_NNS of_IN urinary_JJ
          disturbances_NNS following_VBG clozapine_NN therapy_NN [_NN 3_CD 10_CD 15_CD ]_NN ,_,
          there_EX are_VBP relatively_RB few_JJ reports_NNS of_IN urinary_JJ incontinence_NN
          with_IN risperidone_NN or_CC olanzapine_NN ._. In_IN one_CD report_NN ,_,
          twenty-eight_JJ (_( 28_CD %_NN )_) of_IN patients_NNS on_IN risperidone_NN developed_VBN
          at_IN least_JJS transient_JJ urinary_JJ incontinence_NN ,_, compared_VBN to_TO 13_CD %_NN
          before_IN starting_VBG treatment_NN [_NN 18_CD ]_NN ._. Other_JJ reports_NNS also_RB
          suggest_VBP urinary_JJ incontinence_NN associated_VBN with_IN risperidone_NN
          therapy_NN [_NN 17_CD 19_CD ]_NN ._.
          To_TO date_NN ,_, only_RB one_CD case_NN report_NN of_IN urinary_JJ incontinence_NN
          with_IN olanzapine_NN therapy_NN that_WDT resolved_VBD with_IN ephredrine_NN was_VBD
          found_VBN in_IN the_DT literature_NN [_NN 14_CD ]_NN ._. In_IN the_DT present_JJ study_NN ,_,
          olanzapine_NN had_VBD more_RBR profound_JJ effects_NNS on_IN urodynamic_JJ
          parameters_NNS and_CC the_DT EUS_NNP than_IN risperidone_NN and_CC therefore_RB the_DT
          incidence_NN of_IN urinary_JJ disturbances_NNS in_IN clinical_JJ practice_NN
          would_MD be_VB predicted_VBN to_TO be_VB higher_JJR ._. Olanzapine_NNP is_VBZ a_DT newer_JJR
          compound_NN than_IN clozapine_NN or_CC risperidone_NN and_CC therefore_RB ,_, a_DT
          larger_JJR incidence_NN of_IN urinary_JJ symptoms_NNS with_IN olanzapine_NN
          therapy_NN may_MD await_VB a_DT larger_JJR sampling_VBG ._.
          Finally_RB ,_, possible_JJ side_NN effects_NNS of_IN neuroleptics_NNS ,_, such_JJ
          as_IN urinary_JJ retention_NN ,_, may_MD be_VB predicted_VBN from_IN binding_JJ
          studies_NNS using_VBG human_JJ brain_NN tissue_NN [_NN 12_CD ]_NN if_IN antimuscarinic_JJ
          affinities_NNS will_MD correspond_VB to_TO antimuscarinic_JJ effects_NNS on_IN
          the_DT bladder_NN ._. However_RB ,_, olanzapine_NN and_CC risperidone_NN may_MD also_RB
          result_VB in_IN urinary_JJ disturbances_NNS by_IN their_PRP$ influence_NN on_IN
          central_JJ pathways_NNS mediating_VBG bladder_NN contractions_NNS or_CC
          coordinating_VBG external_JJ urethral_NN sphincter_NN ,_, as_IN may_MD have_VB
          been_VBN the_DT case_NN in_IN the_DT present_JJ study_NN ._. Such_JJ effects_NNS may_MD not_RB
          be_VB readily_RB apparent_JJ or_CC predictable_JJ from_IN receptor_NN binding_JJ
          studies_NNS ._.
        
      
      
        Conclusions_NNP
        Olanzapine_NNP and_CC to_TO a_DT lesser_JJR extent_NN risperidone_NN ,_, altered_VBD
        several_JJ micturition_NN parameters_NNS and_CC they_PRP inhibited_VBD the_DT
        external_JJ urethral_NN sphincter_NN in_IN the_DT anesthetized_JJ rat_NN ._. These_DT
        effects_NNS resulted_VBD in_IN a_DT decreased_VBN effectiveness_NN of_IN the_DT
        bladder_NN to_TO empty_VB as_IN evidenced_VBN by_IN a_DT decreased_VBN micturition_NN
        volume_NN and_CC an_DT increase_NN in_IN the_DT residual_JJ volume_NN ,_, and_CC a_DT
        decreased_VBN activity_NN of_IN the_DT external_JJ urethral_NN sphincter_NN ._.
        Although_IN olanzapine_NN also_RB showed_VBD peripheral_JJ anti-muscarinic_JJ
        effects_NNS on_IN bladder_NN contractions_NNS ,_, risperidone_NN did_VBD not_RB ._.
        Therefore_RB ,_, peripheral_JJ anti-muscarinic_JJ effects_NNS alone_RB cannot_NN
        explain_VBP all_PDT the_DT changes_NNS observed_VBD with_IN these_DT drugs_NNS and_CC they_PRP
        might_MD reflect_VB central_JJ effects_NNS on_IN micturition_NN pathways_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Urodynamic_NNP Studies_NNPS
          The_DT bladder_NN was_VBD emptied_VBN and_CC allowed_VBN to_TO equilibrate_NN to_TO
          air_VB pressure_NN for_IN 5_CD minutes_NNS before_IN beginning_VBG each_DT
          cystometrogram_NN ._. Room_NNP temperature_NN saline_NN was_VBD infused_VBN into_IN
          the_DT bladder_NN (_( 0_CD ._. 11_CD ml_NN /_NN min_NN )_) while_IN recording_NN bladder_NN
          pressure_NN and_CC the_DT infusion_NN was_VBD stopped_VBN when_WRB a_DT contraction_NN
          occurred_VBD ._. Volume_NN expelled_VBN was_VBD determined_VBN by_IN placing_VBG
          cotton_NN gauze_NN at_IN the_DT urinary_JJ meatus_JJ and_CC weighing_VBG before_IN
          and_CC after_IN micturition_NN ._. External_NNP urethral_NN sphincter_NN EMG_NNP
          (_( EUS-EMG_NNP )_) was_VBD recorded_VBN throughout_IN the_DT cystometrogram_NN and_CC
          for_IN sometime_RB after_IN the_DT filling_VBG had_VBN stopped_VBN ._. Cumulative_NNP
          doses_NNS of_IN olanzapine_NN (_( provided_VBN as_IN a_DT courtesy_NN by_IN Ely_NNP Lilly_NNP ,_,
          Indianapolis_NNP ;_: vehicle_NN ,_, 0_CD ._. 01_CD ,_, 0_CD ._. 1_CD ,_, 1_CD mg_NN /_NN kg_NN ;_: n_NN =_SYM 5_LS )_) and_CC
          risperidone_NN (_( RBI_NNP ;_: vehicle_NN ,_, 0_CD ._. 01_CD ,_, 0_CD ._. 1_CD ,_, 1_CD ,_, 10_CD mg_NN /_NN kg_NN ;_: n_NN =_SYM 7_CD )_)
          were_VBD administered_VBN i_NNP ._. v_NN ._. at_IN approximately_RB 10_CD minute_NN
          intervals_NNS ._. The_DT plasma_NN half-life_NN of_IN olanzapine_NN and_CC
          risperidone_NN are_VBP 2_CD ._. 5_CD and_CC 15_CD hr_NN ,_, respectively_RB [_NN 25_CD 49_CD ]_NN ._.
          Both_DT drugs_NNS were_VBD dissolved_VBN in_IN a_DT minimal_JJ amount_NN of_IN 0_CD ._. 1_CD N_NNP
          HCl_NNP ,_, and_CC brought_VBD up_RP to_TO volume_NN with_IN saline_NN (_( final_JJ pH_NN =_SYM 6_CD )_) ._.
          Cystometrograms_NNP were_VBD started_VBN approximately_RB 3_CD minutes_NNS
          after_IN each_DT drug_NN administration_NN ._.
        
        
          Bladder_NNP contractions_NNS induced_VBN by_IN pelvic_JJ nerve_NN
          stimulation_NN
          In_IN order_NN to_TO determine_VB the_DT direct_JJ peripheral_JJ effects_NNS of_IN
          these_DT drugs_NNS on_IN the_DT bladder_NN ,_, the_DT distal_NN end_NN of_IN a_DT pelvic_JJ
          nerve_NN was_VBD stimulated_VBN electrically_RB to_TO elicit_NN a_DT bladder_NN
          contraction_NN (_( n_NN =_SYM 8_CD )_) ._. Both_DT hypogastric_JJ and_CC pelvic_JJ nerves_NNS
          were_VBD cut_VBN before_IN they_PRP entered_VBD the_DT major_JJ pelvic_JJ ganglion_NN
          and_CC a_DT tie_NN was_VBD placed_VBN around_IN the_DT urinary_JJ meatus_JJ to_TO
          preserve_VB isovolumetric_JJ conditions_NNS ._. After_IN infusing_VBG 0_CD ._. 1_CD -_: 0_CD ._. 2_LS
          ml_NN into_IN the_DT bladder_NN the_DT distal_NN ,_, cut_VB end_NN of_IN the_DT pelvic_JJ
          nerve_NN was_VBD stimulated_VBN with_IN a_DT long_JJ train_NN (_( 5_CD Hz_NNP ;_: 1_CD msec_NN
          pulse_NN width_NN ;_: 60_CD sec_NN train_NN ;_: 30_CD -_: 300_CD (_( uamps_NNS )_) to_TO elicit_NN a_DT
          prolonged_JJ contraction_NN displaying_VBG two_CD phases_NNS :_: Phase_NN I_PRP ,_, a_DT
          rapid_JJ contraction_NN and_CC Phase_NN II_NNP ,_, a_DT plateau_NN phase_NN [_NN 20_CD 21_CD ]_NN
          ._. Phase_NN I_PRP is_VBZ resistant_JJ to_TO atropine_NN ,_, and_CC therefore_RB is_VBZ
          mostly_RB due_JJ to_TO non-adrenergic_JJ ,_, non-cholinergic_JJ activation_NN ,_,
          whereas_IN Phase_NN II_NNP is_VBZ highly_RB sensitive_JJ to_TO muscarinic_JJ
          blockade_NN [_NN 21_CD ]_NN ._. Olanzapine_NNP (_( n_NN =_SYM 4_LS )_) and_CC risperidone_NN (_( n_NN =_SYM
          4_LS )_) were_VBD administered_VBN (_( 0_CD ._. 01_CD ,_, 0_CD ._. 1_LS ,_, 1_CD and_CC 10_CD mg_NN /_NN kg_NN ;_: i_NNP ._. v_NN ._. )_) and_CC
          the_DT stimulations_NNS were_VBD repeated_VBN at_IN 10_CD minutes_NNS intervals_NNS ._.
          At_IN the_DT end_NN of_IN each_DT experiment_NN ,_, all_DT rats_NNS were_VBD overdosed_VBN
          with_IN urethane_NN i_NNP ._. v_NN ._.
        
        
          Data_NNP analysis_NN
          Bladder_NNP pressure_NN and_CC EUS-EMG_NNP during_IN the_DT
          cystometrograms_NNS were_VBD displayed_VBN in_IN an_DT electronic_JJ chart_NN
          recorder_NN (_( RC_NNP Electronics_NNP ;_: Goleta_NNP ,_, CA_NNP )_) and_CC analyzed_VBD
          off-line_JJ (_( Dataview_NNP ,_, W_NNP ._. J_NNP ._. Heitler_NNP ,_, U_NNP ._. St_NNP Andrews_NNP ,_,
          Scotland_NNP )_) ._. The_DT following_VBG parameters_NNS were_VBD examined_VBN from_IN
          the_DT cystometrogram_NN as_IN described_VBN in_IN detail_NN earlier_JJR [_NN 7_CD ]_NN :_:
          bladder_NN capacity_NN (_( amount_NN of_IN fluid_JJ infused_VBN to_TO elicit_NN a_DT
          contraction_NN )_) ;_: micturition_NN volume_NN (_( amount_NN of_IN fluid_JJ
          expelled_VBN )_) ;_: residual_JJ volume_NN (_( [_NN bladder_NN capacity_NN -_:
          micturition_NN volume_NN ]_NN /_NN [_NN bladder_NN capacity_NN ]_NN )_) ;_: pressure_NN
          threshold_NN (_( pressure_NN at_IN which_WDT contraction_NN begins_VBZ )_) ;_: peak_NN
          pressure_NN (_( maximal_NN pressure_NN during_IN contraction_NN )_) ;_:
          contraction_NN time_NN ;_: expulsion_NN time_NN (_( time_NN between_IN peak_NN
          pressure_NN and_CC end_NN of_IN high_JJ frequency_NN oscillations_NNS )_) ;_:
          amplitude_NN of_IN high_JJ frequency_NN oscillations_NNS ._. The_DT EMG_NNP
          activity_NN was_VBD examined_VBN by_IN dividing_VBG the_DT bladder_NN contraction_NN
          into_IN three_CD phases_NNS in_IN a_DT modification_NN of_IN the_DT technique_NN of_IN
          Chien_NNP et_CC al_NN ._. [_NN 33_CD ]_NN a_DT contraction_NN phase_NN (_( phase_NN 1_LS )_) ;_: an_DT
          expulsion_NN phase_NN (_( phase_NN 2_LS )_) and_CC a_DT closing_NN phase_NN (_( phase_NN
          3_LS )_) ._.
          The_DT raw_JJ EMG_NNP was_VBD rectified_VBN ,_, integrated_VBN (_( 0_CD ._. 5_LS second_JJ bin_NN )_)
          and_CC the_DT area_NN under_IN curve_NN of_IN the_DT EMG_NNP corresponding_JJ to_TO each_DT
          phase_NN of_IN the_DT bladder_NN contraction_NN was_VBD measured_VBN (_( Sigma_NNP
          Scan_NNP /_NN Image_NN ;_: Jandel_NNP Scientifics_NNP ,_, San_NNP Rafael_NNP ,_, Ca_MD )_) ._. Drug_NN
          effects_NNS were_VBD calculated_VBN as_IN percent_NN of_IN control_NN ._.
          In_IN the_DT case_NN of_IN bladder_NN contractions_NNS induced_VBN by_IN pelvic_JJ
          nerve_NN stimulation_NN ,_, the_DT amplitude_NN of_IN phase_NN A_DT and_CC Phase_NN B_NNP
          were_VBD compared_VBN to_TO drug_NN free_JJ control_NN values_NNS ._.
          Values_NNP are_VBP presented_VBN as_IN Mean_VB ±_NN S_NNP ._. E_NNP ._. M_NNP ._. Repeated_NNP
          measures_NNS ANOVA_NNP (_( GB_NNP Stat_NNP ;_: Dynamic_NNP Microsystems_NNPS ;_: MD_NNP )_) were_VBD
          performed_VBN on_IN all_DT parameters_NNS and_CC when_WRB statistical_JJ
          significance_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) was_VBD obtained_VBN ,_, comparisons_NNS
          between_IN control_NN and_CC different_JJ drug_NN dosages_NNS were_VBD made_VBN
          using_VBG Fisher_NNP 's_POS protected_VBN t-test_JJ [_NN 50_CD ]_NN ._.
        
      
      
        Abbreviations_NNP
        EMG_NNP =_SYM electromyogram_NN EUS_NNP =_SYM external_JJ urethral_NN sphincter_NN
        MAP_NNP =_SYM mean_VB arterial_NN pressure_NN CMG_NNP =_SYM cystometrogram_NN BC_NNP =_SYM
        bladder_NN capacity_NN PT_NNP =_SYM pressure_NN threshold_NN PP_NNP =_SYM peak_NN pressure_NN
        ET_NNP =_SYM expulsion_NN time_NN HFO_NNP =_SYM high_JJ frequency_NN oscillations_NNS MV_NNP =_SYM
        micturition_NN volume_NN RV_NN =_SYM residual_JJ volume_NN CT_NNP =_SYM contraction_NN
        time_NN
      
    
  
